<StructureDefinition xmlns="http://hl7.org/fhir">
  <id value="c779b139-1068-47a5-a60c-90aff090d2cf" />
  <meta>
    <lastUpdated value="2019-06-25T14:42:35.7112029+00:00" />
  </meta>
  <url value="http://ots.nccn.org/hl7/fhir/StructureDefinition/febrileNeutropeniaRisk" />
  <name value="febrileNeutropeniaRisk" />
  <title value="febrileNeutropeniaRisk" />
  <status value="active" />
  <experimental value="false" />
  <date value="2019-06-25T14:42:35.4170632+00:00" />
  <publisher value="National Comprehensive Cancer Network, Inc." />
  <contact>
    <telecom>
      <system value="url" />
      <value value="https://www.nccn.org/about/contact.aspx" />
      <use value="work" />
    </telecom>
  </contact>
  <description value="Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of myelosuppressive chemotherapy that can result in hospitalization and the need for IV antibiotics. FN can also result in dose reductions, delays, or even discontinuation of chemotherapy, which, in turn, may compromise patient outcomes. It is thus important to identify the risk for developing FN so that patients can receive optimal chemotherapy while their risk for FN is appropriately managed." />
  <copyright value="National Comprehensive Cancer Network, Inc. (c) 2017. All right reserved." />
  <fhirVersion value="3.0.1" />
  <kind value="complex-type" />
  <abstract value="false" />
  <contextType value="resource" />
  <context value="PlanDefinition.action" />
  <type value="Extension" />
  <baseDefinition value="http://hl7.org/fhir/StructureDefinition/Extension" />
  <derivation value="constraint" />
  <differential>
    <element id="Extension">
      <path value="Extension" />
      <short value="Febrile neutropenia risk." />
      <definition value="Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of myelosuppressive chemotherapy that can result in hospitalization and the need for IV antibiotics. FN can also result in dose reductions, delays, or even discontinuation of chemotherapy, which, in turn, may compromise patient outcomes. It is thus important to identify the risk for developing FN so that patients can receive optimal chemotherapy while their risk for FN is appropriately managed." />
    </element>
    <element id="Extension.url">
      <path value="Extension.url" />
      <fixedUri value="http://ots.nccn.org/hl7/fhir/StructureDefinition/febrileNeutropeniaRisk" />
    </element>
    <element id="Extension.value[x]:valueCode">
      <path value="Extension.valueCode" />
      <sliceName value="valueCode" />
      <short value="FN risk." />
      <definition value="The level of FN risk associated with this regimen." />
      <comment value="n/a" />
      <min value="1" />
      <type>
        <code value="code" />
      </type>
      <example>
        <label value="FN risk" />
        <valueCode value="high" />
      </example>
      <binding>
        <strength value="required" />
        <description value="FN risk value set." />
        <valueSetUri value="http://ots.nccn.org/fhir/StructureDefinition/febrileNeutropeniaRisk-ValueSet" />
      </binding>
    </element>
  </differential>
</StructureDefinition>